pantoprazole has been researched along with Neoplasms in 8 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Blood samples were collected for pharmacokinetic studies." | 2.79 | A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. ( Bedard, PL; Brana, I; Chen, EX; Douglas, S; Haines, C; Lee, C; Ocana, A; Razak, AR; Siu, LL; Tannock, IF; Wang, L, 2014) |
| "The three FDA-approved cancer drugs developed under repurposing: all-trans-retinoic acid, arsenic trioxide, and thalidomide do not differ in price from other drugs developed under the classical model." | 1.72 | BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal. ( Chavez-Blanco, A; Correa-Basurto, J; Dominguez-Gomez, G; Duenas-Gonzalez, A; Garcia-Martinez, E; Gonzalez-Fierro, A; Romo-Perez, A; Taja-Chayeb, L, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Romo-Perez, A | 1 |
| Dominguez-Gomez, G | 1 |
| Chavez-Blanco, A | 1 |
| Taja-Chayeb, L | 1 |
| Gonzalez-Fierro, A | 1 |
| Garcia-Martinez, E | 1 |
| Correa-Basurto, J | 1 |
| Duenas-Gonzalez, A | 1 |
| Opdam, FL | 1 |
| Modak, AS | 1 |
| Gelderblom, H | 1 |
| Guchelaar, HJ | 1 |
| Brana, I | 1 |
| Ocana, A | 1 |
| Chen, EX | 1 |
| Razak, AR | 1 |
| Haines, C | 1 |
| Lee, C | 1 |
| Douglas, S | 1 |
| Wang, L | 2 |
| Siu, LL | 1 |
| Tannock, IF | 4 |
| Bedard, PL | 1 |
| Shao, T | 1 |
| Templeton, AJ | 1 |
| Jang, R | 1 |
| Vera-Badillo, FW | 1 |
| McNamara, MG | 1 |
| Margolis, M | 1 |
| Kim, TK | 1 |
| Sinaei, M | 1 |
| Shoushtari, H | 1 |
| Tan, Q | 2 |
| Joshua, AM | 1 |
| Saggar, JK | 1 |
| Yu, M | 2 |
| Wang, M | 2 |
| Kanga, N | 1 |
| Zhang, JY | 1 |
| Chen, X | 1 |
| Wouters, BG | 1 |
| Schneider, JL | 1 |
| Kolitsopoulos, F | 1 |
| Corley, DA | 1 |
| Zhang, J | 1 |
| Bristow, RG | 1 |
| Hill, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma[NCT02770378] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pantoprazole and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Breath tests to phenotype drug disposition in oncology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Breath Tests; Cytochrome P-450 Enzym | 2013 |
1 trial available for pantoprazole and Neoplasms
| Article | Year |
|---|---|
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2014 |
5 other studies available for pantoprazole and Neoplasms
| Article | Year |
|---|---|
BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal.
Topics: Apomorphine; Benserazide; Drug Combinations; Humans; Neoplasms; Pantoprazole; Simvastatin; Trimetazi | 2022 |
Use and misuse of waterfall plots.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Combined Chemotherapy Protocols; Clinical Tr | 2014 |
Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antineoplastic Agents; Autophagy; Biomarkers, Tumo | 2015 |
Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; California; Cohort Studies; Dose-R | 2016 |
Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Autophagy; Cell Hypoxia; Cell Line, Tumor; Cell Su | 2016 |